Last reviewed · How we verify
JE Vaccine existing facility
JE Vaccine stimulates the immune system to produce antibodies and cellular immunity against Japanese encephalitis virus.
JE Vaccine stimulates the immune system to produce antibodies and cellular immunity against Japanese encephalitis virus. Used for Prevention of Japanese encephalitis in endemic regions.
At a glance
| Generic name | JE Vaccine existing facility |
|---|---|
| Sponsor | International Centre for Diarrhoeal Disease Research, Bangladesh |
| Drug class | Vaccine |
| Target | Japanese encephalitis virus envelope proteins |
| Modality | Biologic |
| Therapeutic area | Infectious Disease / Immunology |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains inactivated Japanese encephalitis virus or viral antigens that trigger both humoral (antibody) and cell-mediated immune responses. This immunization provides protection against infection by the Japanese encephalitis virus, which is transmitted by Culex mosquitoes in endemic regions of Asia.
Approved indications
- Prevention of Japanese encephalitis in endemic regions
Common side effects
- Local injection site reactions (pain, erythema, swelling)
- Fever
- Headache
- Myalgia
- Fatigue
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: